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Results:	On	 average,	 206	 (range	 164‐230)	 laboratories	 used	 the	OSA	 to	measure	
FVIII	activity	and	30	(range	12‐51)	used	CSA.	The	coefficient	of	variation	of	OSA	and	
CSA	increased	with	lower	FVIII	levels	(FVIII	<0.05	IU/mL).	This	resulted	in	misclassi‐
fication	of	 a	 severe	haemophilia	A	 sample	 into	 a	moderate	or	mild	haemophilia	A	
sample	 in	 4/30	 (13.3%)	 of	CSA	measurements,	while	 this	was	37/139	 (26.6%)	 for	






ments	 is	high	 in	both	OSA	and	CSA	measurements.	The	variation	 in	FVIII	 activity	
levels	 was	 partly	 explained	 by	 specific	manufacturers.	 Further	 standardization	 of	
FVIII	measurements	and	understanding	of	analytical	variation	is	required.


























(CSA).	Most	 laboratories	use	 the	OSA,	which	 is	based	on	 the	ac‐
tivated	 partial	 thromboplastin	 time	 (APTT),	 using	 the	 time	 until	
clot	formation	as	its	endpoint.6	In	the	CSA,	the	coagulation	system	
is	 triggered	resulting	 in	 the	generation	of	 factor	Xa	 (FXa).7	 In	 the	
second	step	of	this	test,	FXa	hydrolyses	a	chromogenic	substrate	
causing	a	colour	change,	which	reflects	the	amount	of	FVIII	activity	
left	 in	 the	 patient	 sample.	 The	 endpoint	 in	 the	CSA	 differs	 from	
that	 in	OSA,	 as	 the	CSA	measures	extinction	 at	 a	plateau	phase.	
Discrepancies	 in	 FVIII	 activity	 levels	 have	 been	 extensively	 re‐
ported	between	 these	 two	assays,	depending	on	 the	mutation	 in	
F8	gene.8,9
Nowadays,	 reagents	 and	 equipment	 to	 perform	 FVIII	 activity	
measurements	are	widely	available.	The	use	of	varying	products	may	
partially	 explain	 the	 between‐laboratory	 variation	 in	 FVIII	 results.	













quality	 assessments	 indeed	 show	 that	 laboratories	 use	 all	 com‐
ponents	 for	 the	FVIII	 assays	 from	one	 company	 in	 a	majority	of	
cases.	Therefore,	ECAT	data	are	highly	suitable	to	investigate	the	
influence	of	company	set‐ups	on	FVIII	activity	level	variation.	The	





2  | MATERIAL AND METHODS






activity	 measurements,	 we	 selected	 sixteen	 samples	 (a)	 with	
FVIII	 activity	 levels	 between	<0.01	 and	 1.94	IU/mL	 (consensus	
values),	 (b)	 measured	 by	more	 than	 10	 laboratories	 by	OSA	 or	
CSA	 and	 (c)	 measured	 between	 2010	 and	 2016.	 As	 expected,	
we	 found	 that	 most	 laboratories	 use	 the	 calibrator,	 activator,	
deficient	plasma	and	equipment	from	one	company	in	the	OSA.	
Therefore,	 three	 groups	 were	 created	 from	 the	 three	 largest	
companies	to	compare	the	CVs	in	the	OSA:	(a)	Siemens,	(b)	Stago	
and	(c)	Werfen.
To	 investigate	 the	 impact	 of	 variation	 on	 hypothetical	 haemo‐
philia	 severity	diagnoses	which	 are	 solely	based	on	 laboratory	 re‐
sults,	FVIII	activity	levels	were	subsequently	classified	according	to	
severity	type	as	stated	by	the	World	Federation	of	Haemophilia.1






the	 ECAT	 surveys	were	 chosen:	 (a)	 a	 severe	 haemophilia	 A	 patient	
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2.3 | Impact of test system on FVIII activity levels 
in the CSA
The	 impact	 of	 different	 test	 systems	 in	 the	CSA	was	 also	 investi‐
gated.	 FVIII	 activity	 levels	were	 compared	 between	Chromogenix	




2.4 | Contribution of deficient plasma and calibrator
As	not	 all	 laboratories	use	 complete	packages	 from	one	manufac‐
turer,	 deficient	 plasma	or	 a	 calibrator	 from	 another	 company	may	
explain	 the	variation	 in	FVIII	 results.	Unfortunately,	 this	 could	not	
be	 investigated	 in	 the	 ECAT	 surveys,	 as	most	 laboratories	 use	 all	
the	components	in	the	test	system	from	one	company.	For	this	rea‐
son,	we	varied	in	deficient	plasma	on	three	different	machines	and	
its	 reagents	 as	 shown	 in	Table	1.	Calibration	 curves	were	 created	
in	 these	 set‐ups.	Using	 these	calibration	curves,	FVIII	 activity	 lev‐
els	were	measured	 in	duplicate	 in	 three	samples;	one	sample	with	
normal	FVIII	activity	levels	(consensus	value	FVIII	1.00	IU/mL),	mild	
haemophilia	 A	 (consensus	 value	 FVIII	 0.34	IU/mL)	 and	 moderate	
haemophilia	A	(consensus	value	FVIII	0.04	IU/mL).




we	 compared	 the	measured	FVIII	 activity	 levels	 of	 the	 calibrators	
with	their	assigned	values.
3  | RESULTS
3.1 | Quantifying variation in FVIII activity 
measurements
In	 the	 different	 surveys,	 on	 average,	 206	 (range	 164‐230)	 lab‐
oratories	 reported	 results	 from	 analyses	 that	 used	 the	OSA	 to	
measure	 FVIII	 activity	 and	 30	 (range	 12‐51)	 laboratories	 used	
the	CSA.	In	surveys	with	lower	FVIII	activity	levels,	the	CV	was	
higher	 (Figure	 1A).	 When	 comparing	 FVIII	 levels	 measured	 by	
OSA	with	 the	 CSA,	 the	 CV	was	 comparable	 between	 the	OSA	
and	the	CSA.	In	addition,	the	median	absolute	FVIII	activity	lev‐
els	 in	 a	 sample	 from	a	 severe	haemophilia	A	patient	were	 simi‐
lar	 in	 the	OSA	 and	CSA,	with	 FVIII	 activity	 levels	 of	 0.005	IU/
mL	 (IQR	 0.005‐0.03	IU/mL)	 for	 the	 CSA	 and	 0.005	IU/mL	 (IQR	
0.005‐0.01	IU/mL)	 for	 the	 OSA.	 When	 comparing	 the	 CV	 be‐
tween	the	laboratories	using	reagents	from	three	companies	for	
the	OSA,	similar	patterns	were	observed.	However,	separation	of	
products	 from	different	 companies	 resulted	 in	higher	CVs	 than	
the	overall	CV	with	a	CV	up	to	158%	maximally	for	the	Werfen	
package	(Figure	1B).




by	 the	 fact	 that	 the	severe	haemophilia	A	sample	was	classified	as	




Calibrator Standard	Human	Plasma STA‐Unicalibrator HemosIL	Cal	Plasma
Activator FVIII	Actin	FS STA‐CK	Prest APTT‐SynthASil
Deficient	plasma FVIII	deficient STA	Immunodef	VIII FVIII	Def.	Plasma
Equipment CS	5100	Sysmex STA‐R	Max ACL	TOP500
TA B L E  1  Set‐up	of	the	different	
packages	when	varying	in	deficient	plasma
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1/8	 (12.5%)	 for	CSA	 testing	with	 Siemens	products.	 In	 conclusion,	
laboratories	using	CSA	misclassified	 severe	haemophilia	A	patients	
less	often.	However,	the	number	of	CSA	measurements	is	small.
3.3 | Impact of test system on FVIII activity levels 
in the OSA
Factor	VIII	 activity	 levels	were	 analysed	 for	 the	 three	major	 com‐
panies	 and	 shown	 in	 Figure	 3.	 In	 a	 sample	 from	 a	 healthy	 person	
(Figure	 3A),	 FVIII	 activity	 levels	 measured	 with	 products	 from	
Werfen	(median	0.93,	IQR	0.88‐0.98	IU/mL)	were	lower	than	FVIII	
activity	 levels	 measured	 by	 products	 from	 Stago	 (median	 1.07,	












3.4 | Impact of test system on FVIII activity levels 
in the CSA
For	 the	CSA,	 three	 kits	were	most	 oftenly	 used:	 (a)	 Chromogenix	





Siemens	had	higher	FVIII	activity	 levels	 in	the	normal	sample	 (me‐
dian	1.02,	 IQR	0.98‐1.09	IU/mL)	compared	to	the	kit	from	Hyphen	
Biomed	(median	0.94,	IQR	0.88‐0.98	IU/mL).
3.5 | Effect of deficient plasma on FVIII activity







ficient	plasma	causes	slightly	 lower	FVIII	 results.	For	example,	 the	
FVIII	activity	level	in	a	Siemens	set‐up	using	Stago	deficient	plasma	
results	in	a	FVIII	level	of	1.00	IU/mL,	while	Siemens	deficient	plasma	
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resulted	 in	 1.11	IU/mL	 and	Werfen	 in	 1.09	IU/mL	 FVIII.	More	 im‐
portantly,	results	obtained	with	Werfen	equipment,	were	in	general	
lower	compared	 to	FVIII	 results	acquired	 from	Stago	and	Siemens	
equipment.	The	average	FVIII	activity	of	the	normal	sample	meas‐
ured	with	Werfen	equipment	was	0.86	IU/mL	while	this	was	1.08	IU/




The	 influence	 of	 the	 calibrator	was	 determined	 by	measuring	 the	
FVIII	activity	 in	each	calibrator	and	comparing	the	measured	FVIII	
activity	value	 to	 the	assigned	value	 from	 the	manufacturer,	based	
on	 the	WHO	 international	 standard.	 The	 FVIII	 levels	 in	 both	 the	
STA‐Unicalibrator	and	the	HemosIL	calibrator	plasmas	were	meas‐
ured	 in	 duplicates	 on	 the	 Siemens	 set‐up	 as	 described	 in	 Table	 1.	
The	assigned	calibration	value	was	1.10	and	0.98	IU/mL	for	the	STA‐
Unicalibrator	 and	 the	 HemosIL,	 respectively,	 while	 the	 measured	
FVIII	activity	levels	of	these	calibrators	were	1.21	and	1.12	IU/mL.	
As	these	values	differed	from	the	assigned	value,	it	may	be	that	the	




tail	 the	 variation	 in	 FVIII	 activity	 measurements	 when	 testing	 by	
OSA	and	CSA	 in	 surveys	 conducted	by	 the	ECAT	external	 quality	
control.	We	showed	that	the	CV	in	FVIII	measurements	has	an	 in‐





The	 results	 of	 this	 study	 showed	 that	 the	 variation	 between	
laboratories	 is	higher	when	FVIII	activity	 levels	are	 lower,	both	 in	













S2).	 The	CV	 increases	 substantially	 in	 samples	with	 low	FVIII	 ac‐
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Factor	 VIII	 activity	 measurements	 were	 slightly	 lower	 when	
measured	with	products	 from	Werfen,	but	 statistically	 significant.	
It	was	impossible	in	the	ECAT	surveys	to	evaluate	the	cause	of	this	
lower	FVIII	activity	by	evaluating	each	component	of	the	OSA	sep‐
arately,	 as	 laboratories	 often	 utilise	 calibrator,	 activator,	 deficient	




exchanging	 deficient	 plasma,	 for	 example,	 deficient	 plasma	 from	
Stago	 in	 a	Siemens	 set‐up.	Despite	 the	 fact	 that	 small	 differences	
were	found,	results	should	be	interpreted	with	caution.	In	general,	
a	small	amount	of	factor	concentrate	may	still	be	present	in	plasma	








be	 the	calibrator.	As	we	 found	a	higher	FVIII	 activity	value	of	 the	
Werfen	calibrator	in	the	Siemens	set‐up,	1.12	IU/mL	instead	of	the	








variation	 in	 both	 assays.	 Firstly,	 of	 course,	 preanalytical	 variables	
may	 influence	 the	 measurements.18,19	 However,	 in	 the	 ECAT	 sur‐
veys,	 these	preanalytical	variables	are	not	applicable	as	all	 labora‐
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